


Remarks/Arguments

Applicants have amended the specification to incorporate the priority claim.

The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Thus, claims 1 and 15 are as originally presented. Claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 14 are currently amended. Claims 12 and 13 are cancelled. No new matter has been added by these amendments. Also, Applicants reserve the right to prosecute any cancelled subject matter in timely-filed continuation applications. Applicants further believe the application is in condition for allowance, and respectfully request the same.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100860-1P US.

Respectfully submitted,



Name: Heidi Berven
Dated: June 17, 2005
Reg. No.: 48,951
Phone No.: 781-839-4336
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760